2999 related articles for article (PubMed ID: 29055842)
21. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
22. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
[TBL] [Abstract][Full Text] [Related]
23. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
[TBL] [Abstract][Full Text] [Related]
24. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
25. The prognostic role of microsatellite instability in colorectal cancer patients.
Micu BV; Andercou O; Vesa SC; Micu CM; Pop TR; Constantea N
Ann Ital Chir; 2017; 6():425-432. PubMed ID: 28874631
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
27. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
Haraldsdottir S; Hampel H; Wu C; Weng DY; Shields PG; Frankel WL; Pan X; de la Chapelle A; Goldberg RM; Bekaii-Saab T
Genet Med; 2016 Sep; 18(9):863-8. PubMed ID: 26866578
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
29. N_LyST: a simple and rapid screening test for Lynch syndrome.
Susanti S; Fadhil W; Ebili HO; Asiri A; Nestarenkaite A; Hadjimichael E; Ham-Karim HA; Field J; Stafford K; Matharoo-Ball B; Hassall JC; Sharif A; Oniscu A; Ilyas M
J Clin Pathol; 2018 Aug; 71(8):713-720. PubMed ID: 29472252
[TBL] [Abstract][Full Text] [Related]
30. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.
Ricker CN; Hanna DL; Peng C; Nguyen NT; Stern MC; Schmit SL; Idos GE; Patel R; Tsai S; Ramirez V; Lin S; Shamasunadara V; Barzi A; Lenz HJ; Figueiredo JC
Cancer; 2017 Oct; 123(19):3732-3743. PubMed ID: 28640387
[TBL] [Abstract][Full Text] [Related]
31. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
Hampel H; Pearlman R; de la Chapelle A; Pritchard CC; Zhao W; Jones D; Yilmaz A; Chen W; Frankel WL; Suarez AA; Cosgrove C; Backes F; Copeland L; Fowler J; O'Malley D; Salani R; McElroy JP; Stanich PP; Goodfellow P; Cohn DE
Gynecol Oncol; 2021 Jan; 160(1):161-168. PubMed ID: 33393477
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome.
Pearlman R; Haraldsdottir S; de la Chapelle A; Jonasson JG; Liyanarachchi S; Frankel WL; Rafnar T; Stefansson K; Pritchard CC; Hampel H
J Med Genet; 2019 Jul; 56(7):462-470. PubMed ID: 30877237
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
[TBL] [Abstract][Full Text] [Related]
36. Success of referral to genetic counseling after positive lynch syndrome screening test.
Irons RF; Contino KM; Horte JJ; Levin B; Mattie KD; Wight M; Kwiatt ME; Behling KC; Edmonston TB; McClane SJ
Int J Colorectal Dis; 2017 Sep; 32(9):1345-1348. PubMed ID: 28664346
[TBL] [Abstract][Full Text] [Related]
37. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice.
Leicher LW; Lammertink MHA; Offerman SR; Morreau H; de Jong MM; de Groot JWB; van Westreenen HL; Vasen HFA; de Vos Tot Nederveen Cappel WH
Scand J Gastroenterol; 2018 May; 53(5):632-636. PubMed ID: 29161904
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
[TBL] [Abstract][Full Text] [Related]
39. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.
Graham RP; Kerr SE; Butz ML; Thibodeau SN; Halling KC; Smyrk TC; Dina MA; Waugh VM; Rumilla KM
Am J Surg Pathol; 2015 Oct; 39(10):1370-6. PubMed ID: 26099011
[TBL] [Abstract][Full Text] [Related]
40. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.
Jiang W; Cai MY; Li SY; Bei JX; Wang F; Hampel H; Ling YH; Frayling IM; Sinicrope FA; Rodriguez-Bigas MA; Dignam JJ; Kerr DJ; Rosell R; Mao M; Li JB; Guo YM; Wu XY; Kong LH; Tang JH; Wu XD; Li CF; Chen JR; Ou QJ; Ye MZ; Guo FM; Han P; Wang QW; Wan DS; Li L; Xu RH; Pan ZZ; Ding PR;
Int J Cancer; 2019 May; 144(9):2161-2168. PubMed ID: 30521064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
